Trent - Robust Expansion Continues With Better Profitability: Motilal Oswal

Ready to launch Star Bazaar; prioritizing Westside, Zudio and Star

Westside store interior. (Source: Company official fb page)

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

The discretionary category continues to see muted demand, but Trent Ltd. has far outpaced the industry. It delivered industry-leading like-for-like growth of 10% and hence gained market share over other retailers in the apparel segment (especially in value format).

Further, despite aggressive store addition, it has limited balance sheet risk or weakness in operations. Trent’s industry-leading revenue growth is mainly driven by:

  1. strong same-store sales growth and productivity,

  2. healthy footprint additions, and

  3. Zudio’s strong value proposition.

Trent’s successful store performance, healthy store economics, and aggressive growth strategy offer a huge runway for growth over the next three-to-five years. Star’s improving store metrics further offer a further opportunity.

We have raised our standalone revenue/Ebitda estimates by 4%/6% for FY25/FY26, factoring in higher store addition for Zudio.

We estimate a CAGR of 36%/34% in standalone revenue/Ebitda over FY24-26, led by 23% store addition and healthy same-store sales growth, which justify the premium valuation for the stock.

We have ascribed 54 times to standalone business, two times enterprise value/sales to Star Bazaar, and 15 times EV/Ebitda to Zara to arrive at our target price of Rs 5,500. Adjusting Star’s and Zara’s values, the stock is trading at 82 times FY26E EPS for the standalone business. Retain Buy.

Click on the attachment to read the full report:

Motilal Oswal Trent Update.pdf
Read Document

Also Read: Mankind Pharma - Disruptor With A Dose Of Care; Motilal Oswal Initiates Coverage With A Buy

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story You must be an existing Premium User
Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit. Feel free to Add NDTV Profit as trusted source on Google.
GET REGULAR UPDATES
Add us to your Preferences
Set as your preferred source on Google